Fast Onset Of Action Of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports On-Demand Treatment In Hemophilia A Mice

Background: Patients with Hemophilia A or B with and without inhibitors lack treatment options that are fast and easy to use for treating acute bleeding. Currently, their only options are intravenous administration of replacement or bypass therapies. Marzeptacog alfa (activated) (MarzAA) is a novel increased potency recombinant FVIIa in clinical development. We hypothesized that, in addition to its clinically demonstrated efficacy in SC prophylaxis, MarzAA could potentially be used SC on-demand to control acute hemorrhage after bleeding has started.